Insider Buying: Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) CFO Acquires 40,000 Shares of Stock

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) CFO James M. Frates acquired 40,000 shares of the company’s stock in a transaction that occurred on Thursday, September 12th. The shares were acquired at an average price of $2.53 per share, with a total value of $101,200.00. Following the completion of the transaction, the chief financial officer now owns 233,464 shares in the company, valued at $590,663.92. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Amylyx Pharmaceuticals Stock Up 1.1 %

NASDAQ AMLX traded up $0.03 on Monday, hitting $2.65. The company’s stock had a trading volume of 732,382 shares, compared to its average volume of 2,120,145. The company’s 50-day moving average is $2.12 and its 200 day moving average is $2.84. The firm has a market cap of $180.22 million, a PE ratio of -2.49 and a beta of -0.62. Amylyx Pharmaceuticals, Inc. has a 1-year low of $1.58 and a 1-year high of $19.95.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.73) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.35). The company had revenue of ($1.02) million during the quarter, compared to analyst estimates of $18.83 million. Amylyx Pharmaceuticals had a negative net margin of 17.86% and a negative return on equity of 15.51%. During the same quarter in the previous year, the company earned $0.31 earnings per share. On average, equities analysts expect that Amylyx Pharmaceuticals, Inc. will post -2.27 EPS for the current year.

Institutional Trading of Amylyx Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its stake in shares of Amylyx Pharmaceuticals by 1.4% in the 1st quarter. Vanguard Group Inc. now owns 5,348,139 shares of the company’s stock valued at $15,189,000 after purchasing an additional 72,573 shares during the last quarter. AQR Capital Management LLC boosted its position in Amylyx Pharmaceuticals by 2,768.0% during the second quarter. AQR Capital Management LLC now owns 3,340,943 shares of the company’s stock valued at $6,348,000 after acquiring an additional 3,224,454 shares during the last quarter. Almitas Capital LLC acquired a new stake in Amylyx Pharmaceuticals during the 2nd quarter worth about $3,617,000. Franklin Resources Inc. grew its holdings in Amylyx Pharmaceuticals by 114.4% during the 4th quarter. Franklin Resources Inc. now owns 1,325,001 shares of the company’s stock worth $19,504,000 after acquiring an additional 707,134 shares during the period. Finally, Goldman Sachs Group Inc. raised its position in shares of Amylyx Pharmaceuticals by 5.9% in the 4th quarter. Goldman Sachs Group Inc. now owns 1,256,861 shares of the company’s stock worth $18,501,000 after acquiring an additional 69,733 shares in the last quarter. 95.84% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the stock. The Goldman Sachs Group lifted their price target on shares of Amylyx Pharmaceuticals from $3.00 to $4.00 and gave the company a “neutral” rating in a report on Friday, July 12th. HC Wainwright reaffirmed a “buy” rating and set a $8.00 target price on shares of Amylyx Pharmaceuticals in a research note on Wednesday, July 10th. Six research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and an average target price of $17.60.

Amylyx Pharmaceuticals Company Profile

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.